Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Rising leverage • Persistent cash burn NUVB offers strong liquidity and improving loss trends, but persistent cash burn, rising debt, and premium valuation keep the risk profile high.
Price Behavior
Key Price Behavior Insights: • Support holding • Resistance capped • Neutral momentum Support Level: $6.60–$6.72 Resistance Level: $7.10–$7.26 NUVB is cautiously constructive last month above $6.60–$6.72, but a breakout above $7.10 and $7.26 is needed for bullish confirmation, while a close below $6.60 risks a pullback.
Sentiment & News
Key News Insights: • IBTROZI Momentum • Safusidenib Fast Track • Strong Cash Runway Nuvation Bio's strong IBTROZI launch, advancing safusidenib program, and robust cash position support bullish analyst sentiment despite speculative-risk concerns.
AI Summary
NUVB is now an early commercial oncology story, with IBTROZI's $23.2M quarterly sales validating demand, but investors should require sustained quarter-over-quarter revenue growth and improving cash burn before underwriting consensus upside, while viewing safusidenib as high-value but unproven pipeline optionality.
Description
Nuvation Bio is a clinical-stage biopharmaceutical company developing small-molecule therapies for oncology, with its lead candidate NUV-422 targeting CDK2, CDK4 and CDK6. Its pipeline also includes oral inhibitors affecting BET proteins, Wee1 kinase, and adenosine receptors, along with a drug–drug conjugate platform that pairs PARP inhibition with cytotoxic warheads to treat cancers including ER+ breast and ovarian tumors. The company was founded in 2018, rebranded from RePharmation in 2019, and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 5 | Jan 12 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop. | Closed | -24.8% |
| Sep 15 | Sep 22 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s near-term FDA approval and early commercial launch of IBTROZI™, strong cash runway, and positive technical signals with a 13.8% gain over three weeks establish it as a hot idea, balanced with caution on volatility and rising leverage risks before more commercial data emerge. | Closed | +3.8% |